Home / Deep Research / Gaucher Disease

Gaucher Disease

1. Disease Information

2026-04-25
Falcon MONDO:0018150 Model: Edison Scientific Literature 41 citations

1. Disease Information

1.1 Concise overview

Gaucher disease (GD) is a lysosomal storage disorder caused by deficient activity of lysosomal acid β-glucosidase / glucocerebrosidase (GCase), leading to lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivative glucosylsphingosine (GlcSph; lyso‑Gb1), particularly in macrophages, resulting in multi-organ disease (visceral, hematologic, skeletal; and sometimes neurologic) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2, dardis2022patientcenteredguidelines pages 1-2).

Clinical types (classical): - Type 1 (GD1): non-neuronopathic; accounts for ~90–95% of cases (cojbasicUnknownyeardiagnosisandmanagement pages 5-8, rossi2023noninvasivedbsbasedapproaches pages 1-2). - Type 2 (GD2): acute neuronopathic; rare, often fatal in early childhood (cojbasicUnknownyeardiagnosisandmanagement pages 5-8). - Type 3 (GD3): chronic neuronopathic; less common than GD1 (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

1.2 Key identifiers and controlled vocabulary

  • MONDO: MONDO_0018150 (carubbi2026glucosylsphingosine(lysogb1)an pages 1-2)
  • OMIM (clinical types):
  • GD1: 230800
  • GD2: 230900
  • GD3: 231000 (carubbi2026glucosylsphingosine(lysogb1)an pages 1-2)
  • MeSH: D005776 (“Gaucher Disease”) (from ClinicalTrials.gov browse module) (NCT07223944 chunk 1, NCT05324943 chunk 1).
  • Orphanet, ICD‑10, ICD‑11: Not explicitly present in the retrieved full-text excerpts/trial records; therefore not asserted here.

1.3 Common synonyms / alternative names (as used in retrieved sources)

1.4 Evidence provenance (patient vs aggregated)

The information in this report is primarily derived from aggregated resources: international guideline synthesis (Dardis et al. 2022), narrative reviews (Giuffrida et al. 2023; Rossi et al. 2023), a population screening cohort (Chang et al. 2024), real-world registry analysis (GOS registry; Zimran et al. 2025), mechanistic animal-model work (Lin et al. 2024), and ClinicalTrials.gov trial records (chang2024newbornscreeningfor pages 1-2, dardis2022patientcenteredguidelines pages 8-9, zimran2025evaluationoflysogb1 pages 1-2, lin2024intrinsiclinkbetween pages 1-2, NCT05324943 chunk 1).

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in GBA1 encoding GCase (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, dardis2022patientcenteredguidelines pages 1-2, dubiela2024longandshortterm pages 1-2).

Important alternative genetic etiology (Gaucher-like biochemistry/phenotype): If clinical/biochemical features are consistent with GD but no pathogenic GBA1 variants are found, international laboratory guidelines recommend considering saposin C deficiency and analyzing PSAP (prosaposin gene) (dardis2022patientcenteredguidelines pages 10-12).

2.2 Risk factors

  • Genetic: biallelic pathogenic GBA1 variants are causal (dardis2022patientcenteredguidelines pages 1-2). The diagnostic guideline notes extensive allelic heterogeneity; HGMD lists 540 GBA1 variants, with 403 associated with GD (dardis2022patientcenteredguidelines pages 9-10).
  • Population ancestry: incidence is higher in Ashkenazi Jewish populations (e.g., ~1 in 450–1,000 live births reported by a biomarker review) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).

2.3 Protective factors

No protective genetic or environmental factors were explicitly identified in the retrieved excerpts.

2.4 Gene–environment interactions

No explicit gene–environment interaction studies were identified in the retrieved excerpts. However, precision-genomics work argues that phenotypic heterogeneity may reflect multi-locus genetic contributions (saith2024concurrentgeneticdisorders pages 1-3, saith2025precisiongenomicprofiling pages 1-2).

3. Phenotypes

3.1 Core phenotype spectrum (with approximate frequencies where available)

From a recent clinical summary excerpt, common clinical findings include: - Splenomegaly: >90% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Hepatomegaly: 60–80% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Thrombocytopenia: ~90% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) - Anemia: 30–50% (cojbasicUnknownyeardiagnosisandmanagement pages 5-8) Skeletal involvement is common and may become irreversible if advanced (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

Neurologic involvement distinguishes GD2 (acute severe) and GD3 (chronic neuronopathic) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 1-2).

3.2 Phenotype characteristics

  • Onset: ranges from infancy (especially GD2) to adulthood; GD2 typically presents in the first year of life and may be fatal early (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
  • Progression: variable; neurologic disease is progressive and generally not improved by current systemic therapies that do not cross the blood–brain barrier (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

3.3 Quality-of-life impact

The retrieved excerpts do not provide standardized QoL instrument statistics (EQ‑5D/SF‑36). Bone disease and cytopenias plausibly drive morbidity, but such statements require additional QoL-specific sources.

3.4 Suggested HPO terms (examples)

Based on phenotypes explicitly discussed in retrieved sources: - Splenomegaly (HP:0001744) - Hepatomegaly (HP:0002240) - Thrombocytopenia (HP:0001873) - Anemia (HP:0001903) - Bone pain / skeletal dysplasia / osteonecrosis (multiple; skeletal involvement is explicit but granular HPO mapping would require additional phenotype-specific papers) (cojbasicUnknownyeardiagnosisandmanagement pages 5-8, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Pathogenic variant spectrum and genotype–phenotype examples

4.3 Modifier genes and “multi-locus” contributions (recent work)

Mechanistic modifier evidence (animal model): - A 2024 mechanistic study reports that progranulin (PGRN; GRN) acts as a modifier of GCase biology and disease severity. In Grn−/− mice with graded Gba1 D409V dosages, higher mutant dosage produced earlier onset/shorter lifespan and more severe inflammation, lysosomal–autophagy dysfunction, gliosis, and α‑synuclein increases, supporting a threshold model for severity (lin2024intrinsiclinkbetween pages 1-2).

Human cohort precision-genomics evidence: - In a deeply phenotyped cohort with WES, ~6–6.5% of GD patients had additional genetic diagnoses contributing to “expanded/atypical” phenotypes, suggesting that some GD presentations behave as multi-locus disorders (saith2024concurrentgeneticdisorders pages 3-5, saith2024concurrentgeneticdisorders pages 1-3). - Example cohort statistics: among 275 patients, 18 (6.5%) had expanded phenotypes (preprint) (saith2024concurrentgeneticdisorders pages 3-5) and 17 (6.2%) had atypical phenotypes (peer-reviewed version) (saith2025precisiongenomicprofiling pages 1-2).

4.4 Epigenetics / chromosomal abnormalities

No epigenetic or chromosomal-abnormality evidence was identified in the retrieved excerpts.

5. Environmental Information

No specific environmental, lifestyle, or infectious triggers were identified in the retrieved excerpts as causal contributors to GD. (GD is primarily genetic.)

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

  1. GBA1 pathogenic variants → reduced/mislocalized GCase activity (dardis2022patientcenteredguidelines pages 1-2).
  2. Impaired lysosomal degradation of GlcCer → ceramide → accumulation of GlcCer and GlcSph (lyso‑Gb1) (dardis2022patientcenteredguidelines pages 1-2, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).
  3. Lipid-laden macrophages (“Gaucher cells”) infiltrate liver, spleen, bone marrow → organomegaly, cytopenias, and bone disease (rossi2023noninvasivedbsbasedapproaches pages 1-2, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
  4. In neuronopathic forms and in modifier contexts, lysosomal dysfunction intersects with neuroinflammation, gliosis, autophagy disruption, and α‑synuclein pathology (lin2024intrinsiclinkbetween pages 1-2).

6.2 Molecular pathways / cellular processes (from retrieved mechanistic sources)

Precision-genomic and mechanistic sources emphasize lipid-driven metabolic inflammation and lysosome-autophagy disruption: - “The accumulation of GlcCer and GlcSph in GD activates a range of pathways, including those involving inflammasomes, iron metabolism, necroptosis, ferroptosis, lysosomal function, autophagy, and reactive oxygen species (ROS).” (Saith et al. 2024 preprint excerpt) (saith2024concurrentgeneticdisorders pages 11-13). - PGRN/GRN modifier work demonstrates dose-dependent substrate accumulation, inflammatory responses, lysosomal–autophagy dysfunction, microgliosis, and α‑synuclein increases in mouse models (lin2024intrinsiclinkbetween pages 1-2).

6.3 Suggested ontology terms

7. Anatomical Structures Affected

7.1 Organ level (commonly affected)

7.2 Tissue/cell level

7.3 Subcellular level

7.4 Suggested UBERON terms (examples)

  • Spleen; liver; bone marrow; brain.

8. Temporal Development

  • Onset: can be pediatric or adult depending on subtype and genotype (cojbasicUnknownyeardiagnosisandmanagement pages 5-8).
  • Progression: variable; neurologic forms are progressive and currently poorly addressed by standard ERT/SRT (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

9. Inheritance and Population

9.1 Inheritance pattern

9.2 Epidemiology (key recent/reviewed statistics)

Estimates vary across sources and populations: - General population incidence reported as ~1/40,000–1/60,000 (review) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) and GD1 incidence ~1/40,000–1/86,000 in non-Jewish populations (review) (rossi2023noninvasivedbsbasedapproaches pages 1-2). - In Ashkenazi Jews, incidence reported as ~1/450–1,000 live births (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) and also ~1 in 850 in one registry-based review excerpt (zimran2025evaluationoflysogb1 pages 1-2). - Reported overall incidence range: 0.4–5.8 per 100,000 births and prevalence 0.7–1.8 per 100,000 (review) (rossi2023noninvasivedbsbasedapproaches pages 1-2).

9.3 Newborn screening (2024 data)

A 2024 Shanghai cohort screened 50,108 newborns for 6 LSDs by MS/MS on DBS and confirmed 2 Gaucher diagnoses among 27 total LSD diagnoses; the combined 6-LSD birth prevalence was 1 in 1,856 live births, with 11.1% early-onset and 88.9% later-onset/subclinical forms among confirmed LSDs (chang2024newbornscreeningfor pages 1-2). This supports real-world feasibility of large-scale screening but Gaucher-specific precision is limited by the small number of Gaucher cases in this combined assay (chang2024newbornscreeningfor pages 1-2).

10. Diagnostics

10.1 Clinical tests and laboratory confirmation

Core principle (guideline-level): GD diagnosis requires biochemical demonstration of deficient GCase/BGLU activity and confirmatory molecular testing where possible (dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 8-9).

Gold-standard specimens: peripheral blood leukocytes and/or cultured skin fibroblasts (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 8-9).

DBS (dried blood spot): recommended as a first-line screen, but any low activity result must be confirmed in leukocytes/fibroblasts; DBS BGLU testing has low positive predictive value and should not be used alone for diagnosis (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 10-12).

Diagnostic enzyme-activity threshold: <15% of normal in leukocyte/fibroblast homogenates is diagnostic (dardis2022patientcenteredguidelines pages 7-8, dardis2022patientcenteredguidelines pages 8-9).

Abstract-supported quote (guideline): Dardis et al. emphasize that “Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder due to the deficient activity of the acid beta-glucosidase (GCase) enzyme, resulting in the progressive lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivate, glucosylsphingosine (GlcSph).” (dardis2022patientcenteredguidelines pages 1-2).

10.2 Biomarkers

Lyso‑Gb1 (GlcSph): - Widely characterized as a highly sensitive and specific biomarker for diagnosis and treatment monitoring (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2, zimran2025evaluationoflysogb1 pages 1-2). - Treatment decision support: a cohort study found a DBS lyso‑Gb1 cutoff >250 ng/mL was associated with initiation of GD-specific therapy (sensitivity 71%, specificity 87.5%), with treated patients showing higher median lyso‑Gb1 than untreated at diagnosis (dinur2023contributionofglucosylsphingosine pages 6-7). - Treatment monitoring dynamics: - Short-term: average 17% decrease 30 minutes after ERT infusion in 20 patients (dubiela2024longandshortterm pages 1-2). - Longitudinal: real-world registry analysis shows median change −8.6 ng/mL in treated vs +25.0 ng/mL untreated, and +19.5 ng/mL in those stopping treatment (zimran2025evaluationoflysogb1 pages 1-2).

Chitotriosidase: useful but lacks specificity and is confounded by common CHIT1 loss-of-function duplication; guideline notes interpretive complications (dardis2022patientcenteredguidelines pages 4-5, dubiela2024longandshortterm pages 1-2).

10.3 Genetic testing strategy (implementation considerations)

Guideline highlights: - GBA1 testing is complicated by a highly homologous pseudogene and recombinant alleles; some methods miss large deletions/recombinants; enzymatic confirmation is mandatory when variants of uncertain significance occur (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10). - If GD phenotype/biochemistry but no GBA1 variants: consider PSAP/saposin C deficiency (dardis2022patientcenteredguidelines pages 10-12).

11. Outcome / Prognosis

The retrieved excerpts do not provide modern, quantitative survival curves stratified by treatment era. They do note that ERT/SRT improved visceral/hematologic disease (especially GD1), while neuronopathic manifestations remain largely unresponsive to standard systemic therapies (kulkarni2024advancementsinviral pages 10-12, cojbasicUnknownyeardiagnosisandmanagement pages 5-8).

12. Treatment

12.1 Standard disease-specific therapy (real-world implementation)

Enzyme replacement therapy (ERT): long-established cornerstone, generally effective for visceral and hematologic manifestations in GD1, but limited for neurologic disease (blood–brain barrier) (kulkarni2024advancementsinviral pages 10-12, giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2). - A review excerpt reports typical dosing 15–120 units/kg every 2 weeks, with most clinical/lab/radiologic improvements within ~6 months (except irreversible skeletal disease) (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2).

Substrate reduction therapy (SRT): improves visceral/hematologic manifestations and is used in adults with GD1; does not address CNS disease adequately (kulkarni2024advancementsinviral pages 10-12).

12.2 Biomarker-informed management

Lyso‑Gb1 is increasingly used to guide treatment decisions and monitor therapy response, including identifying when treatment may be indicated among mildly affected patients and detecting response after starting or stopping ERT (dinur2023contributionofglucosylsphingosine pages 6-7, zimran2025evaluationoflysogb1 pages 1-2).

12.3 Emerging/advanced therapeutics (2023–2024 prioritized)

Rationale: current ERT/SRT do not cross the blood–brain barrier and do not improve neuronopathic manifestations, motivating gene therapy strategies (kulkarni2024advancementsinviral pages 10-12).

AAV liver-directed gene therapy (GD1)

  • FLT201 (GALILEO-1; NCT05324943): Phase 1, completed; single IV infusion of replication-incompetent ssAAV; n=6 adults with GD1; primary outcome TEAEs through Week 38 (ClinicalTrials.gov) (NCT05324943 chunk 1).
  • FLT201 (GALILEO-3; NCT07223944): Phase 3, recruiting; single IV infusion; n=45 planned; evaluates stable hemoglobin at Week 52 after discontinuation of ERT/SRT (ClinicalTrials.gov) (NCT07223944 chunk 1).

AAV systemic gene therapy targeting peripheral disease (GD/GD1)

  • LY3884961 / PR001 (PROCEED; NCT05487599): Phase 1/2, recruiting; single IV dose; outcomes include safety, spleen volume, platelets, GCase levels, GlcSph levels, and ability to discontinue/reinitiate ERT/SRT (ClinicalTrials.gov) (NCT05487599 chunk 1).

CNS-directed gene therapy for neuronopathic GD2

  • VGN-R08b (NCT06272149): Early Phase 1, recruiting; AAV9-human GBA1 delivered intracerebroventricularly in infants ≤24 months; endpoints include safety and survival at 24 months, plus GCase activity and Lyso‑GL1 in blood/CSF (ClinicalTrials.gov) (NCT06272149 chunk 1).

Ex vivo autologous HSC lentiviral gene therapy

  • AVR‑RD‑02 (Guard1; NCT04145037): Phase 1/2, terminated voluntarily (not for safety/medical reasons). Product is autologous CD34+ HSCs modified ex vivo by lentiviral vector encoding codon-optimized GCase, with busulfan conditioning (ClinicalTrials.gov) (NCT04145037 chunk 1).

Visual evidence note: Kulkarni et al. 2024 summarize multiple current clinical trials and identifiers in a dedicated section; the retrieved cropped images support these program listings (kulkarni2024advancementsinviral media cabb2850, kulkarni2024advancementsinviral media 3ff0cbdf).

12.4 Suggested MAXO terms (examples)

  • Enzyme replacement therapy
  • Substrate reduction therapy
  • Gene therapy
  • Hematopoietic stem cell transplantation / autologous HSC gene therapy

13. Prevention

13.1 Primary prevention

Not applicable in the classic sense for a Mendelian recessive disorder, but reproductive and carrier-screening strategies are relevant.

13.2 Secondary prevention (early detection)

Newborn screening: MS/MS-based screening with confirmatory biochemical/genetic testing can identify affected newborns, including later-onset forms; 2024 Shanghai data demonstrate implementation at scale (chang2024newbornscreeningfor pages 1-2).

13.3 Genetic counseling

The laboratory guideline emphasizes genetic testing as the most reliable method to identify carriers and recommends pre/post-test genetic counseling (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10).

14. Other Species / Natural Disease

No naturally occurring veterinary Gaucher disease evidence was identified in the retrieved excerpts.

15. Model Organisms

Mechanistic and therapeutic-development work relies heavily on mouse models of GD, including modifier models and neuronopathic models. A 2024 mechanistic study used genetically engineered mouse models combining PGRN deficiency with graded Gba1 D409V dosages to demonstrate threshold-like effects on severity, neuroinflammation, lysosome-autophagy dysfunction, and α‑synuclein accumulation (lin2024intrinsiclinkbetween pages 1-2).

Recent developments (2023–2024 emphasis) and real-world applications (high-yield highlights)

  1. Biomarker maturation into clinical decision support: A 2023 cohort study proposed DBS lyso‑Gb1 >250 ng/mL as associated with initiation of GD-specific therapy among newly diagnosed patients, with ROC-derived 71% sensitivity / 87.5% specificity, while cautioning about inter-laboratory variability (dinur2023contributionofglucosylsphingosine pages 6-7).
  2. Real-world monitoring feasibility: Registry analysis using DBS lyso‑Gb1 showed treatment initiation or withdrawal produced directionally consistent biomarker changes in hundreds of adults, supporting routine monitoring in practice (zimran2025evaluationoflysogb1 pages 1-2).
  3. Population-scale screening implementation (2024): Shanghai MS/MS NBS screened >50k newborns and confirmed 2 Gaucher diagnoses within a 6-LSD panel, while highlighting that most confirmed LSD cases were later-onset/subclinical forms, informing counseling/management (chang2024newbornscreeningfor pages 1-2).
  4. Acceleration of gene therapy pipelines: A 2024 gene-therapy review documents multiple ongoing AAV and lentiviral programs and emphasizes the central limitation of standard therapies for neuronopathic disease due to blood–brain barrier constraints (kulkarni2024advancementsinviral pages 10-12, kulkarni2024advancementsinviral media cabb2850).

Evidence summary table

Table (click to expand)
Topic Key findings Evidence type Source (first author, year, journal or registry) Publication date URL PMID Notes
Diagnostics / genetics International Working Group guideline: fluorometric leukocyte/fibroblast GCase assay is gold standard; DBS may be used first-line for screening but must be confirmed in leukocytes or fibroblasts; enzyme activity <15% of normal in leukocyte/fibroblast homogenates is diagnostic; >400 pathogenic GBA1 variants reported in abstract/background and 540 variants (403 GD-associated) noted in guideline text; GBA1 testing is complicated by a highly homologous pseudogene and recombinant alleles; ~10% of patients may carry large deletions/recombinant alleles; two diagnostic algorithms provided (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 9-10, dardis2022patientcenteredguidelines pages 1-2, dardis2022patientcenteredguidelines pages 7-8) Guideline Dardis, 2022, Orphanet Journal of Rare Diseases Dec 2022 https://doi.org/10.1186/s13023-022-02573-6 not in retrieved text Important limitation: DBS BGLU has poor positive predictive value and cannot stand alone for diagnosis; variants should be ACMG-classified; consider PSAP/saposin C deficiency if phenotype/biochemistry fit but GBA1 is negative (dardis2022patientcenteredguidelines pages 8-9, dardis2022patientcenteredguidelines pages 10-12)
Biomarkers / epidemiology / treatment Lyso-Gb1 review: GD incidence estimated ~1/450–1,000 live births in Ashkenazi Jews, ~1/40,000–60,000 in general population; North-East Italy newborn-screening estimate 1/16,063; ERT typically 15–120 U/kg every 2 weeks; lyso-Gb1 described as the most promising biomarker with higher sensitivity/specificity than chitotriosidase (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2) Review Giuffrida, 2023, Orphanet Journal of Rare Diseases Feb 2023 https://doi.org/10.1186/s13023-023-02623-7 not in retrieved text Narrative review; stresses biomarker utility but exact cross-lab cutoffs vary (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2)
Biomarkers / treatment decision Retrospective cohort of 97 newly diagnosed patients: 65 started GD-specific therapy; median lyso-Gb1 337 ng/mL in treated vs 153.5 ng/mL in untreated; proposed DBS cutoff >250 ng/mL associated with treatment initiation with 71% sensitivity and 87.5% specificity (dinur2023contributionofglucosylsphingosine pages 6-7) Cohort study Dinur, 2023, International Journal of Molecular Sciences Feb 2023 https://doi.org/10.3390/ijms24043945 not in retrieved text Authors caution that inter-laboratory methodology/units prevent direct universal adoption of this exact cutoff (dinur2023contributionofglucosylsphingosine pages 6-7)
Diagnostics / epidemiology / newborn screening DBS-centered review/case-based report: incidence 0.4–5.8 per 100,000 births, prevalence 0.7–1.8 per 100,000; GD1 about 90% of cases; GD1 incidence in non-Jewish populations ~1/40,000–1/86,000, GD2 ~1/150,000, GD3 ~1/200,000; tissue glycolipids may rise 20–100×; illustrates first- and second-tier DBS workflow with low GCase and elevated lyso-Gb1 followed by molecular confirmation (rossi2023noninvasivedbsbasedapproaches pages 1-2) Review / case-based diagnostic report Rossi, 2023, Biomedicines Sep 2023 https://doi.org/10.3390/biomedicines11102672 not in retrieved text Useful for NBS-style workflows; not a population screening program outcome paper for GD alone (rossi2023noninvasivedbsbasedapproaches pages 1-2, rossi2023noninvasivedbsbasedapproaches pages 10-11)
Biomarkers / treatment monitoring Eight-year ERT biomarker dynamics: GD1 coefficient of variation 34% vs GD3 23% (p=0.0003); in short-term testing, lyso-Gb1 fell by 17% within 30 min post-ERT (p<0.0001) in 20 patients; prior data summarized in paper show lyso-Gb1 can fall from median ~200 ng/mL pre-ERT to <50 ng/mL after ERT (dubiela2024longandshortterm pages 1-2) Observational biomarker study Dubiela, 2024, Biomolecules Jul 2024 https://doi.org/10.3390/biom14070842 not in retrieved text Highlights substantial intra-individual/inter-infusion variability; DBS timing relative to infusion matters (dubiela2024longandshortterm pages 1-2)
Newborn screening / epidemiology Shanghai cohort of 50,108 newborns screened for 6 LSDs by MS/MS on DBS: 353 screened positive; 27 confirmed LSDs (1 in 1,856 live births overall), including 2 Gaucher cases; among all LSD diagnoses, 3/27 (11.1%) early-onset and 24/27 (88.9%) later-onset/subclinical forms (chang2024newbornscreeningfor pages 1-2) Cohort newborn-screening study Chang, 2024, JAMA Network Open May 13, 2024 https://doi.org/10.1001/jamanetworkopen.2024.10754 not in retrieved text Combined 6-LSD study, so Gaucher-specific prevalence estimate is based on only 2 cases; still highly relevant for real-world NBS implementation (chang2024newbornscreeningfor pages 1-2)
Biomarkers / registry / treatment outcomes Gaucher Outcome Survey real-world study: of 2,007 registry participants, 435 met inclusion criteria; median lyso-Gb1 change from baseline to last assessment: −8.6 ng/mL in treated, +25.0 ng/mL untreated, +19.5 ng/mL after stopping treatment; treatment-naive had −120.5 ng/mL vs previously treated −3.3 ng/mL; velaglucerase alfa subgroup −32.6 ng/mL (zimran2025evaluationoflysogb1 pages 1-2) Registry study Zimran, 2025, Orphanet Journal of Rare Diseases Jan 2025 https://doi.org/10.1186/s13023-024-03444-y not in retrieved text Strong real-world support for lyso-Gb1 as a treatment-response biomarker using DBS; observational, not randomized (zimran2025evaluationoflysogb1 pages 1-2)
Gene therapy / GD1 GALILEO-1 first-in-human study of FLT201: NCT05324943; Phase 1, open-label, single-group; 6 adults with GD1; single intravenous dose of a replication-incompetent ssAAV vector; primary outcome was treatment-emergent adverse events through Week 38; eligibility required stable ERT/SRT for at least 2 years and deficient GCase activity ≤30% of normal at diagnosis (NCT05324943 chunk 1, kulkarni2024advancementsinviral media cabb2850) Clinical trial record ClinicalTrials.gov / Spur Therapeutics, NCT05324943 First posted Apr 13, 2022; completed Dec 4, 2024 https://clinicaltrials.gov/study/NCT05324943 not in retrieved text Focused on safety/tolerability plus GCase augmentation; excludes splenectomy and anti-AAVS3 neutralizing antibodies (NCT05324943 chunk 1)
Gene therapy / GD1 confirmatory study GALILEO-3 confirmatory FLT201 study: NCT07223944; Phase 3, non-randomized, single-group; estimated 45 adults with GD1 on stable ERT/SRT ≥2 years; single intravenous ssAAV FLT201 infusion; primary endpoint: proportion with stable hemoglobin (decrease no more than 1.5 g/dL) at Week 52 after discontinuing ERT/SRT (NCT07223944 chunk 1) Clinical trial record ClinicalTrials.gov / Spur Therapeutics, NCT07223944 First posted Nov 3, 2025; recruiting as of Apr 21, 2026 https://clinicaltrials.gov/study/NCT07223944 not in retrieved text Outside 2022–2025 publication window but highly relevant as latest implementation trajectory; MeSH term listed as Gaucher Disease D005776 in record (NCT07223944 chunk 1)
Gene therapy / GD peripheral disease PROCEED: NCT05487599 of LY3884961 (PR001); Phase 1/2, multicenter, open-label, dose-finding; estimated 15 adults; single intravenous dose of replication-incompetent recombinant AAV; outcomes include AEs, spleen volume, platelet count, GCase, GlcSph, and time to discontinuation/re-initiation of ERT/SRT over 5 years (NCT05487599 chunk 1) Clinical trial record ClinicalTrials.gov / Prevail Therapeutics, NCT05487599 First posted Aug 4, 2022; recruiting as of Apr 15, 2026 https://clinicaltrials.gov/study/NCT05487599 not in retrieved text Requires centrally confirmed bi-allelic GBA1 variants and stable therapy; anti-AAV9 antibody titer must be ≤1:40 (NCT05487599 chunk 1)
Gene therapy / ex vivo HSC lentiviral Guard1: NCT04145037 of AVR-RD-02; Phase 1/2, multinational open-label study; actual enrollment 8; intervention is autologous CD34+ HSCs genetically modified ex vivo with lentiviral vector encoding codon-optimized GCase, with busulfan conditioning; follow-up 52 weeks; sponsor states termination was voluntary and not based on safety or medical reasons (NCT04145037 chunk 1) Clinical trial record ClinicalTrials.gov / AVROBIO, NCT04145037 First posted Oct 30, 2019; results posted Jan 18, 2024 https://clinicaltrials.gov/study/NCT04145037 not in retrieved text Important proof-of-concept for cell-based gene therapy; small sample, early termination limits efficacy interpretation (NCT04145037 chunk 1)
Gene therapy / neuronopathic GD2 VGN-R08b exploratory trial: NCT06272149; Early Phase 1, single-center, open-label, dose-climbing/expansion; estimated 6 infants ≤24 months with GD2; AAV9-human GBA1 delivered by intracerebroventricular injection; primary endpoint AEs/SAEs at Week 52; secondary endpoints include survival at 24 months, GCase activity, GC, and Lyso-GL1 in blood and CSF, plus immunogenicity (NCT06272149 chunk 1) Clinical trial record ClinicalTrials.gov / Xinhua Hospital, NCT06272149 First posted Feb 22, 2024 https://clinicaltrials.gov/study/NCT06272149 not in retrieved text Especially relevant for CNS-targeted therapy where ERT/SRT have limited neurologic benefit; excludes anti-AAV9 neutralizing antibody titer >1:5 (NCT06272149 chunk 1)

Table: This table compiles recent high-yield evidence items for Gaucher disease across diagnostics, biomarkers, epidemiology, newborn screening, and emerging gene therapy. It is structured for direct use in a disease knowledge base and emphasizes quantitative thresholds, trial metadata, and implementation caveats.

Limitations of this report (due to retrieved-source constraints)

  • ICD‑10/ICD‑11 and Orphanet identifiers were not explicitly present in the retrieved full text excerpts/trial records, and therefore were not asserted.
  • PMIDs were not provided in the retrieved text chunks for several items (especially MDPI journals and ClinicalTrials.gov records); thus, PMID fields are marked “not in retrieved text” in the summary table.
  • Some requested elements (e.g., standardized QoL statistics, comprehensive differential diagnosis lists, and detailed epigenetic profiling) require additional targeted retrieval beyond the current evidence set.

References

  1. (carubbi2026glucosylsphingosine(lysogb1)an pages 1-2): Francesca Carubbi, Silvia Linari, and Marco Spada. Glucosylsphingosine (lyso-gb1): an update on its use as a biomarker in gaucher disease. International Journal of Molecular Sciences, 27:1705, Feb 2026. URL: https://doi.org/10.3390/ijms27041705, doi:10.3390/ijms27041705. This article has 2 citations.

  2. (giuffrida2023glucosylsphingosine(lysogb1)as pages 1-2): Gaetano Giuffrida, Uros Markovic, Annalisa Condorelli, Valeria Calafiore, Daniela Nicolosi, Marianna Calagna, Stephanie Grasso, Marco Tindaro Valentino Ragusa, Jennifer Gentile, and Mariasanta Napolitano. Glucosylsphingosine (lyso-gb1) as a reliable biomarker in gaucher disease: a narrative review. Orphanet Journal of Rare Diseases, Feb 2023. URL: https://doi.org/10.1186/s13023-023-02623-7, doi:10.1186/s13023-023-02623-7. This article has 58 citations and is from a peer-reviewed journal.

  3. (rossi2023noninvasivedbsbasedapproaches pages 1-2): Claudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, Mirco Zucchelli, Carlotta Buccolini, Sara Di Rado, Daniela Trotta, Liborio Stuppia, Luca Federici, and Maurizio Aricò. Noninvasive dbs-based approaches to assist clinical diagnosis and treatment monitoring of gaucher disease. Biomedicines, 11:2672, Sep 2023. URL: https://doi.org/10.3390/biomedicines11102672, doi:10.3390/biomedicines11102672. This article has 12 citations.

  4. (dardis2022patientcenteredguidelines pages 1-2): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.

  5. (cojbasicUnknownyeardiagnosisandmanagement pages 5-8): I Ćojbašić. Diagnosis and management of gaucher disease: current approaches and emerging. Unknown journal, Unknown year.

  6. (NCT07223944 chunk 1): A Gaucher Disease Gene Therapy Trial With FLT201. Spur Therapeutics. 2026. ClinicalTrials.gov Identifier: NCT07223944

  7. (NCT05324943 chunk 1): A Gene Therapy Study in Patients With Gaucher Disease Type 1. Spur Therapeutics. 2022. ClinicalTrials.gov Identifier: NCT05324943

  8. (chang2024newbornscreeningfor pages 1-2): Siyu Chang, Xia Zhan, Yuchao Liu, Huanlei Song, Zizhen Gong, Lianshu Han, Gustavo H. B. Maegawa, Xuefan Gu, and Huiwen Zhang. Newborn screening for 6 lysosomal storage disorders in china. JAMA Network Open, 7:e2410754, May 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.10754, doi:10.1001/jamanetworkopen.2024.10754. This article has 21 citations and is from a peer-reviewed journal.

  9. (dardis2022patientcenteredguidelines pages 8-9): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.

  10. (zimran2025evaluationoflysogb1 pages 1-2): Ari Zimran, Shoshana Revel-Vilk, Tama Dinur, Majdolen Istaiti, Jaco Botha, Elena Lukina, Pilar Giraldo, Patrick Deegan, and Stephan vom Dahl. Evaluation of lyso-gb1 as a biomarker for gaucher disease treatment outcomes using data from the gaucher outcome survey. Orphanet Journal of Rare Diseases, Jan 2025. URL: https://doi.org/10.1186/s13023-024-03444-y, doi:10.1186/s13023-024-03444-y. This article has 9 citations and is from a peer-reviewed journal.

  11. (lin2024intrinsiclinkbetween pages 1-2): Yi Lin, Xiangli Zhao, Benjamin Liou, Venette Fannin, Wujuan Zhang, Kenneth D R Setchell, Xiaohong Wang, Dao Pan, Gregory A Grabowski, Chuan-ju Liu, and Ying Sun. Intrinsic link between pgrn and gba1 d409v mutation dosage in potentiating gaucher disease. Human molecular genetics, 33:1771-1788, Aug 2024. URL: https://doi.org/10.1093/hmg/ddae113, doi:10.1093/hmg/ddae113. This article has 6 citations and is from a domain leading peer-reviewed journal.

  12. (dubiela2024longandshortterm pages 1-2): Pawel Dubiela, Paulina Szymanska-Rozek, Piotr Hasinski, Patryk Lipinski, Grazina Kleinotiene, Dorota Giersz, and Anna Tylki-Szymanska. Long- and short-term glucosphingosine (lyso-gb1) dynamics in gaucher patients undergoing enzyme replacement therapy. Biomolecules, 14:842, Jul 2024. URL: https://doi.org/10.3390/biom14070842, doi:10.3390/biom14070842. This article has 5 citations.

  13. (dardis2022patientcenteredguidelines pages 10-12): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.

  14. (dardis2022patientcenteredguidelines pages 9-10): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.

  15. (saith2024concurrentgeneticdisorders pages 1-3): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.

  16. (saith2025precisiongenomicprofiling pages 1-2): Armaan Saith, Noor Ul Ain, Jiapeng Ruan, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Precision genomic profiling in gaucher disease: insights from atypical presentations. Frontiers in Genetics, Nov 2025. URL: https://doi.org/10.3389/fgene.2025.1553036, doi:10.3389/fgene.2025.1553036. This article has 0 citations and is from a peer-reviewed journal.

  17. (kulkarni2024advancementsinviral pages 10-12): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.

  18. (saith2024concurrentgeneticdisorders pages 3-5): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.

  19. (saith2024concurrentgeneticdisorders pages 11-13): Armaan Saith, Jiapeng Ruan, Noor Ul Ain, Maniya Kasaiyan, Dhanpat Jain, Gary Israel, Sameet Mehta, Nigel S. Bamford, Shiny Nair, and Pramod K. Mistry. Concurrent genetic disorders in gaucher disease: insights into complex phenotypes, genetic modifiers, and targeted therapies. Unknown journal, Dec 2024. URL: https://doi.org/10.20944/preprints202412.1836.v1, doi:10.20944/preprints202412.1836.v1.

  20. (NCT06272149 chunk 1): An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT06272149

  21. (dardis2022patientcenteredguidelines pages 7-8): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.

  22. (dinur2023contributionofglucosylsphingosine pages 6-7): Tama Dinur, Peter Bauer, Christian Beetz, Claudia Cozma, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs, Volha Skrahina, Ari Zimran, and Shoshana Revel-Vilk. Contribution of glucosylsphingosine (lyso-gb1) to treatment decisions in patients with gaucher disease. International Journal of Molecular Sciences, 24:3945, Feb 2023. URL: https://doi.org/10.3390/ijms24043945, doi:10.3390/ijms24043945. This article has 16 citations.

  23. (dardis2022patientcenteredguidelines pages 4-5): A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. Aerts, and the International Working Group of Gaucher Disease. Patient centered guidelines for the laboratory diagnosis of gaucher disease type 1. Orphanet Journal of Rare Diseases, Dec 2022. URL: https://doi.org/10.1186/s13023-022-02573-6, doi:10.1186/s13023-022-02573-6. This article has 70 citations and is from a peer-reviewed journal.

  24. (NCT05487599 chunk 1): A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED). Prevail Therapeutics. 2022. ClinicalTrials.gov Identifier: NCT05487599

  25. (NCT04145037 chunk 1): Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease. AVROBIO. 2019. ClinicalTrials.gov Identifier: NCT04145037

  26. (kulkarni2024advancementsinviral media cabb2850): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.

  27. (kulkarni2024advancementsinviral media 3ff0cbdf): Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, and Tae-Un Han. Advancements in viral gene therapy for gaucher disease. Genes, 15:364, Mar 2024. URL: https://doi.org/10.3390/genes15030364, doi:10.3390/genes15030364. This article has 16 citations.

  28. (rossi2023noninvasivedbsbasedapproaches pages 10-11): Claudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, Mirco Zucchelli, Carlotta Buccolini, Sara Di Rado, Daniela Trotta, Liborio Stuppia, Luca Federici, and Maurizio Aricò. Noninvasive dbs-based approaches to assist clinical diagnosis and treatment monitoring of gaucher disease. Biomedicines, 11:2672, Sep 2023. URL: https://doi.org/10.3390/biomedicines11102672, doi:10.3390/biomedicines11102672. This article has 12 citations.